|Bid||73.09 x 1200|
|Ask||73.17 x 800|
|Day's Range||72.93 - 73.38|
|52 Week Range||49.24 - 73.92|
|Beta (5Y Monthly)||0.32|
|PE Ratio (TTM)||29.74|
|Forward Dividend & Yield||1.04 (1.44%)|
|Ex-Dividend Date||Aug 14, 2020|
|1y Target Est||N/A|
Novo Nordisk (NVO) files for a label expansion of Ozempic in the EU to include a new dose of 2.0 mg.
Novo Nordisk (NVO) files application in Europe for the label expansion of subcutaneous Ozempic (semaglutide) 2.4 mg.
Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end of September. At Insider Monkey, we follow nearly 817 active hedge funds and notable investors and by analyzing their 13F filings, we can determine the stocks that they are […]